Author Archives: William Looney

Paring the Fat in Clinical Trials

By William Looney | Published: July 18, 2012
Is too much irrelevant data slogging the pace to registration? Conclusions of a Pharm Exec May 15 Roundtable on finding ways to build efficiencies into an increasingly costly and complex clinical trials process have been bolstered by new research from the Tufts Center for the Study of Drug Development. Based on extensive survey data drawn [...]
Posted in Op-Ed, R&D | Tagged , | 3 Comments

TB: A Faster Pace in Progress Against the Wasting Disease

By William Looney | Published: June 11, 2012
Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV.  More important, multidrug resistant TB is now found in [...]
Posted in Global | Tagged , , | 1 Comment

Strategic Patient Adherence Awards: This Year's Winner…

By William Looney | Published: May 11, 2012
CBI conference highlights three turnaround strategies to plug the gaps in patient adherence. New insights into customer behavior fostered by the revolution in information technology are finally being applied to the age-old quandary of why most patients stop taking prescribed medications after a few months of therapy. This was a key conclusion of last month’s [...]
Posted in Events, patient compliance | Tagged , | 1 Comment

Cat Fight on Co-Pay Offsets

By William Looney | Published: March 14, 2012
Suing for the Drug Company Suet Pharm Exec is no fortune teller, but our guest author Mason Tenaglia was positively clairvoyant in his January feature on the tussle between pharmacy benefit managers [PBMs] and brand name drug manufacturers over the use of co-pay and discount cards to limit out-of-pocket costs for patients. As predicted, the [...]
Posted in healthcare | Tagged , , , , | 2 Comments

Patient Assistance Programs: Are They Still Relevant?

By William Looney | Published: March 12, 2012
One of the key reputational assets of Big Pharma is the patient assistance program [PAP], which provides patented innovative medicines to needy patients for free or at a nominal charge – it’s the industry’s own branded version of the social safety net. But a shifting landscape of government fiscal pressures, economic decline and the erratic [...]
Posted in Regulatory, healthcare | Tagged , , , , , | Leave a comment